Cytotoxicity Screen of Mangiferin and its Major Metabolite Norathyriol in Human Tumor Cell Lines
Poster Apr 04, 2012
Souza, J.R.R., Feitosa, J.P.A., Ricardo, N.M.P.S, Trevisan, M.T.S., Frei, E., Ulrich C.M., Owen, R.W.
Many natural products are available worldwide as potential chemoprotective agents against commonly occurring cancers, for example Mangiferin which has low bioavaiulability and is thought to be mainly available in the colon.
Many studies have shown that human fecal bacteria (HFB) can have a great impact on polyphenol metabolism and that bioconverted forms of polyphenols (metabolites) probably have more biological importance than the native form present in diets.
Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy TargetsPoster
The human immune system is comprised of a complex network of immune checkpoint receptors that are promising new immunotherapy targets for the treatment of a variety of diseases including cancer and autoimmune-mediated disorders.READ MORE
Novel lead optimization strategy of BACE I inhibitors for the treatment of Alzheimer’s disease by Quantitative Structure-Activity Relationship (QSAR) and Physiologically-Based Pharmacokinetics (PBPK) modelingPoster
In this study, we introduce an innovative in silico-based high throughput lead optimization strategy with QSAR and PBPK modelings using StarDrop™, ADMET predictor® and GastroPlus®.READ MORE
Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell LinesPoster
Inecalcitol is a vitamin D receptor agonist currently in Phase II clinical trial in AML (acute myeloid leukemia). Inecalcitol increases the expression of CD38 at the surface of 5 multiple myeloma cell lines; therefore, inecalcitol could potentiate the clinical response of MM patients to a therapeutic anti-CD38 antibody
Inecalcitol induces the expression of the CD38 antigen at the surface of 4 AML cell lines; thus, inecalcitol could render AML patients sensitive to a therapeutic anti-CD38.